Cancer prevention

Allterum Therapeutics receives $12 million product development grant from CPRIT to advance anti-CD127 therapeutic antibody into clinic

Retrieved on: 
Monday, April 8, 2024
NCI, Acute lymphoblastic leukemia, CLL, Immunotherapy, AML, TTC, Lung, Patient, ALL, NeXT, National Cancer Institute, Breast, Cancer, Pediatrics, Doctor of Philosophy, IND, GMP, Clinical trial, Investigational New Drug, Therapy, Immune system, Prognosis, Research institute, Cancer prevention, FDA, Lymphoma, CD127, Pharmaceutical industry

HOUSTON, April 8, 2024 /PRNewswire-PRWeb/ -- Allterum Therapeutics, Inc. has been awarded a $12 million product development grant from the Cancer Prevention and Research Institute of Texas (CPRIT), which will support the clinical evaluation of Allterum's lead candidate, 4A10, a monoclonal antibody targeting CD127. CD127 is a receptor that is expressed in major subsets of multiple cancers including hematological cancers (ALL, AML, CLL, and lymphoma) and solid tumors (lung, breast, colorectal, H&N, esophageal cancers).

Key Points: 
  • Allterum Therapeutics, Inc. has been awarded a $12 million product development grant from the Cancer Prevention and Research Institute of Texas (CPRIT).
  • HOUSTON, April 8, 2024 /PRNewswire-PRWeb/ -- Allterum Therapeutics, Inc. has been awarded a $12 million product development grant from the Cancer Prevention and Research Institute of Texas (CPRIT), which will support the clinical evaluation of Allterum's lead candidate, 4A10, a monoclonal antibody targeting CD127.
  • An addition to the $12M Product Development Award, Allterum received a $2.9M CPRIT seed award in 2020, which supported early-stage development work for the 4A10 antibody and laid the foundation for the current grant.
  • "We are pleased to provide Allterum with this TTC product development award to advance their promising anti-cancer drug into clinic," said Dr. Kenneth Smith, CPRIT's Chief Product Development Officer.

Plus Therapeutics Announces Validation & Clinical Implementation of CSF-01 Leptomeningeal Cancer Cell Diagnostic

Retrieved on: 
Monday, March 25, 2024
Diagnosis, Certification, LM, Plus Therapeutics, NSCLC, CSF, Partnership, Central nervous system, Patient, CNS, Breast, PSTV, Lung cancer, Clinical trial, Therapy, Cancer, Rhenium, CLIA, Research institute, Cancer prevention, Feinberg School of Medicine, Associate professor

AUSTIN, Texas, March 25, 2024 (GLOBE NEWSWIRE) --  Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, today announced it has successfully completed key validation testing and implementation of its tumor cell enumeration assay, known as CSF-01, to be used initially as an exploratory endpoint in its ReSPECT-LM clinical trials.

Key Points: 
  • “In mid-2023, the Company licensed CSF-01, as well as a broader CSF diagnostic testing portfolio due to high conviction that routine implementation will substantially improve diagnosis and clinical management of LM,” said Marc H. Hedrick, M.D., President & CEO of Plus Therapeutics.
  • While validated for use in Plus’ clinical development programs, full Clinical Laboratory Improvement Amendments (CLIA) certification is not anticipated until 2025.
  • The ReSPECT-LM trial, including support for CSF-01 testing, is currently receiving grant funding from the Cancer Prevention and Research Institute of Texas (CPRIT).
  • If the FORSEE data is positive, we intend to work toward increasing commercial reimbursement for the CLIA-certified test and explore partnerships to maximize diagnostic utilization for the broader CNS cancer space.

UT Health San Antonio secures $16.4 million from CPRIT over six months, adding transformative expertise, bolstering cancer research

Retrieved on: 
Friday, March 8, 2024
Doctor of Philosophy, Education, MD, Drug development, DNA repair, National Cancer Institute, Breast, University, RNA, Research institute, Ovarian cancer, Cell Systems, Health, Genetics, Anatomy, Biochemistry, Bangladesh Technical Education Board, Algorithm, Adolescence, Nursing, Neoplasm, Kitagawa, Faculty, Dentistry, HPV, Child, DNA, Chromatin, Therapy, SAN, National Institutes of Health, Mentorship, Chromosome instability, Doctor of Pharmacy, Structural biology, Vaccination, Cancer Research Institute, Molecular medicine, News, Laboratory, Research, University of Texas System, Cedars-Sinai Medical Center, Survivor, BRCA2, Cell, Howard Hughes Medical Institute, School, Cancer prevention, Luan, BRCA1, Patient, Teaching, Ewing sarcoma, Cancer, Public, Vaccine

SAN ANTONIO, March 7, 2024 /PRNewswire-PRWeb/ -- The University of Texas Health Science Center at San Antonio (UT Health San Antonio) (https://uthscsa.edu/) has secured approximately $16.4 million in funding from the Cancer Prevention and Research Institute of Texas (https://www.cprit.state.tx.us/about-us) the past six months, attracting three top cancer researchers and advancing child and adolescent cancer research.

Key Points: 
  • SAN ANTONIO, March 7, 2024 /PRNewswire-PRWeb/ -- The University of Texas Health Science Center at San Antonio (UT Health San Antonio) ( https://uthscsa.edu/ ) has secured approximately $16.4 million in funding from the Cancer Prevention and Research Institute of Texas ( https://www.cprit.state.tx.us/about-us ) the past six months, attracting three top cancer researchers and advancing child and adolescent cancer research.
  • The Mays Cancer Center at UT Health San Antonio ( https://cancer.uthscsa.edu/ ) is one of only four National Cancer Institute-designated Cancer Centers in Texas.
  • The Mays Cancer Center provides leading-edge cancer care, propels innovative cancer research and educates the next generation of leaders to end cancer in South Texas.
  • The Greehey Children's Cancer Research Institute ( https://cancer.uthscsa.edu/gccri ) is one of only two institutes in the United States dedicated solely to pediatric cancer research.

ChromaCode Announces Appointment of Mark McDonough as Chairman

Retrieved on: 
Wednesday, January 10, 2024
Memorial, Chairperson, Pharming, NGS, Medicine, Biotechnology, Princeton University, Molecular biology, Credit Suisse, Cancer prevention, Genomics, Laboratory, Research institute, Biomarker, Retirement, Doctor of Philosophy, NEA, Nested polymerase chain reaction, Management

CARLSBAD, Calif., Jan. 10, 2024 /PRNewswire/ -- ChromaCode, Inc., a pioneering genomics multiplexing platform company developing accessible and affordable laboratory-based solutions, announces Mark McDonough as Chair of the Board, the retirement of former Chair Carol Gallagher, Pharm.D., and the appointment of Michele Park, Ph.D. to the Board.

Key Points: 
  • CARLSBAD, Calif., Jan. 10, 2024 /PRNewswire/ -- ChromaCode, Inc., a pioneering genomics multiplexing platform company developing accessible and affordable laboratory-based solutions, announces Mark McDonough as Chair of the Board, the retirement of former Chair Carol Gallagher, Pharm.D., and the appointment of Michele Park, Ph.D. to the Board.
  • Mark McDonough, CEO of ChromaCode, becomes Chair of the Board, effective January 1, 2024.
  • Retiring Chair, Carol Gallagher commented, "A year ago, we were fortunate to have Mark join ChromaCode as CEO.
  • Now, we are thrilled to announce the appointment of Mark as Chair of our Board of Directors.

Plus Therapeutics Partners With K2bio for Development of Novel Tests for Cerebrospinal Fluid (CSF) Tumor Cell and Molecular Biomarker Analyses

Retrieved on: 
Tuesday, December 12, 2023
CSF, Patient, Ecosystem, Partnership, Neoplasm, Cerebrospinal fluid, Learning, PSTV, Cancer prevention, Caregiver, Research, FDA, Doctor of Philosophy, Cancer, Therapy, CNS, Texas Medical Center, LM, Plus Therapeutics, Central nervous system, Diagnosis, Rhenium, Fast Track, Research institute

This trial is currently receiving grant funding through The Cancer Prevention and Research Institute of Texas (CPRIT).

Key Points: 
  • This trial is currently receiving grant funding through The Cancer Prevention and Research Institute of Texas (CPRIT).
  • K2bio is based in Houston and is part of the Texas Medical Center life sciences ecosystem specializing in all aspects of translational cancer diagnostic and therapeutic research and development.
  • “K2bio is a leader in enabling rapid diagnostic and therapeutic progress for innovative companies such as Plus,” said Colby Suire, PhD, acting President and CEO of K2bio.
  • Patients interested in learning more about the ReSPECT-LM trial can visit ClinicalTrials.gov ( NCT05034497 ).

Salarius Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides a Business Update

Retrieved on: 
Thursday, May 11, 2023
Topotecan, GLP, Carcinoma, Abstract, Rituximab, LSD1, AACR, Cancer prevention, Follicular lymphoma, DLBCL, European Hematology Association, Multiple myeloma, Venetoclax, Non-Hodgkin lymphoma, Biotechnology, Clinical trial, Lenalidomide, NHL, CD20, American Association for Cancer Research, Cyclophosphamide, Salinicola salarius, SCLC, Bortezomib, Congress, Investigational New Drug, Hematological Cancer Research Investment and Education Act, Patient, Toxicology, Neoplasm, Ewing sarcoma, Research institute, Research, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, IND, News, Food, Cancer Prevention and Research Institute of Texas, Vaccine, Pharmaceutical industry, Fine chemical, Cryptocurrency, Video game

HOUSTON, May 11, 2023 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company using protein inhibition and protein degradation to develop cancer therapies for patients in need of new treatment options, today reported financial results for the three months ended March 31, 2023 and provided a business update.

Key Points: 
  • Cash and cash equivalents were $9.3 million as of March 31, 2023, compared with $12.1 million as of December 31, 2022.
  • The decline reflects lower spending on seclidemstat in the 2023 quarter and one-time expenses of $2.0 million related to the purchase of the targeted protein degrader program in the 2022 quarter.
  • “In addition, Salarius continued to execute on plan during the first quarter of 2023 and recent weeks as we advanced the development of SP-3164, our targeted protein degrader.
  • Salarius will be participating in the 2023 BIO International Convention in Boston June 5-8, and the European Hematology Association 2023 Congress in Frankfurt, Germany June 8-11.

TripleBlind Announces Collaboration with Two University of Texas Health-Related Institutions to Advance Public Health Cancer Prevention

Retrieved on: 
Wednesday, March 29, 2023
University of Texas Southwestern Medical Center, MLS, WHNP-BC, University, Moses Austin, Cancer prevention, University of Texas System, University of Texas Health Science Center at San Antonio, Principal investigator, Cancer Prevention and Research Institute of Texas, University of Texas at Austin, Division, DRS, Research, Privacy, Electronic health record, APRN, Doctor of Philosophy, Hepatitis C, Hospital, Patient, HIPAA, Internal medicine, Diagnosis, Research institute, Health, MPH, Death, HCC, Infection, Software, Pharmaceutical industry, Medical device, FIDSA, MD

KANSAS CITY, Mo., March 29, 2023 (GLOBE NEWSWIRE) -- TripleBlind , the leader in automated, real-time data de-identification, today announced an agreement with The University of Texas Southwestern Medical Center and The University of Texas Health Science Center at San Antonio.

Key Points: 
  • KANSAS CITY, Mo., March 29, 2023 (GLOBE NEWSWIRE) -- TripleBlind , the leader in automated, real-time data de-identification, today announced an agreement with The University of Texas Southwestern Medical Center and The University of Texas Health Science Center at San Antonio.
  • With the help of TripleBlind's technology, the agreement aims to empower researchers to study the impact collaborative research has on quality of patient care.
  • The Cancer Prevention and Research Institute of Texas (CPRIT) recently announced $90 million in new grant funding for programs to address the need for better cancer prevention across Texas, including public health screening and treatment for Hepatitis C and Hepatitis B vaccination in patients from low-income South Texas communities.
  • Hepatitis C, a condition that is increasing in younger populations, is a cause of hepatocellular carcinoma liver cancer (HCC), which is the third leading cause of death worldwide .

Salarius Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

Retrieved on: 
Monday, March 27, 2023
Myelodysplastic syndrome, Abstract, Rituximab, AACR, University, Cell death, ASH, Cancer prevention, Sarcoma, Multiple myeloma, Drug discovery, Clinical trial, Bone marrow, Lenalidomide, NHL, Chronic myelomonocytic leukemia, American Association for Cancer Research, The University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences, Research, MD Anderson Cancer Center, Monroe Dunaway Anderson, Salinicola salarius, Azacitidine, Protein, Acquisition, Patent, Patient, Mouse, Research institute, Ewing sarcoma, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, IND, Society, Factorization of polynomials, Food, Cancer Prevention and Research Institute of Texas, Cryptocurrency, Video game, Pharmaceutical industry, Rail freight transport, Vaccine

HOUSTON, March 27, 2023 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company using protein inhibition and protein degradation to develop cancer therapies for patients in need of new treatment options, today reported financial results for the three and 12 months ended December 31, 2022 and provided a business update.

Key Points: 
  • Cash and cash equivalents were $12.1 million as of December 31, 2022, compared with $29.2 million as of December 31, 2021.
  • Research and development expenses were $4.7 million in the fourth quarter of 2022, compared with $2.7 million in the fourth quarter of 2021.
  • As of December 31, 2022, Salarius had cash, cash equivalents and restricted cash of $12.1 million, compared with $29.2 million as of December 31, 2021.
  • Current cash and cash equivalents are expected to fund the company’s planned operations into the fourth quarter of 2023.

Salarius Pharmaceuticals Receives $1.48 Million from the Cancer Prevention and Research Institute of Texas

Retrieved on: 
Thursday, February 16, 2023
Organization, Effectiveness, Salinicola salarius, FET, Patient, Cancer prevention, Clinical trial, Cancer Prevention and Research Institute of Texas, Food, Research, Cyclophosphamide, Ewing sarcoma, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Research institute, Topotecan, Pharmaceutical industry

(NASDAQ: SLRX), a clinical-stage biopharmaceutical company using protein inhibition and protein degradation to develop cancer therapies for patients in need of new treatment options, announces the receipt of a $1.48 million payment under its contract with the Cancer Prevention and Research Institute of Texas (CPRIT).

Key Points: 
  • (NASDAQ: SLRX), a clinical-stage biopharmaceutical company using protein inhibition and protein degradation to develop cancer therapies for patients in need of new treatment options, announces the receipt of a $1.48 million payment under its contract with the Cancer Prevention and Research Institute of Texas (CPRIT).
  • This $1.48 million payment brings Salarius’ cumulative disbursement from CPRIT to approximately $16.0 million.
  • To date, CPRIT has awarded over $3 billion in grants to Texas research institutions and organizations through its academic research, prevention and product development research programs.
  • Salarius was awarded a product development research grant in May 2016 for the development of seclidemstat, and the disbursements are based upon Salarius’ achievement of defined goals and objectives.

J.B. Hunt Announces Induction Into the Anderson Assembly Society at MD Anderson Cancer Center

Retrieved on: 
Thursday, January 5, 2023
Professional Services, Philanthropy, Oncology, Other Transport, Trucking, Rail, Maritime, Air, Transport, Other Philanthropy, Health, Logistics, Supply Chain Management, Environmental, Social and Governance (ESG), Education, Cancer, Control, Partnership, Cancer prevention, MD, Research, Monroe Dunaway Anderson, News, MD Anderson Cancer Center, J. B. Hunt, Health, Analysis, Patient, Mortality, Policy, University, Anderson, Institute of World Economy and International Relations, Hospital, JBHT, U.S. News & World Report, Public health, Quality of life, Incidence, Immigration Control Platform, Management, Pharmaceutical industry

J.B. Hunt Transport Services, Inc. (NASDAQ: JBHT), one of the largest supply chain solutions providers in North America, announced today it has been inducted into the Anderson Assembly at The University of Texas MD Anderson Cancer Center, a society created to recognize philanthropic donors who have made a lifetime commitment to supporting the mission of MD Anderson.

Key Points: 
  • J.B. Hunt Transport Services, Inc. (NASDAQ: JBHT), one of the largest supply chain solutions providers in North America, announced today it has been inducted into the Anderson Assembly at The University of Texas MD Anderson Cancer Center, a society created to recognize philanthropic donors who have made a lifetime commitment to supporting the mission of MD Anderson.
  • “MD Anderson is an organization that is dear to J.B. Hunt as many of our employees utilize their expertise and resources,” said Brad Hicks, president of highway services and executive vice president of people at J.B. Hunt.
  • With J.B. Hunt’s philanthropic support, MD Anderson will be able to use data to better aid medically-underserved communities, ultimately expanding support across the U.S.
    “J.B.
  • As part of its induction into the Anderson Assembly, J.B. Hunt will be featured in MD Anderson’s Faces of Philanthropy Exhibit - an onsite museum showcase for donor stories and how philanthropy has impacted the organization.